ClinicalTrials.gg
RecruitingNCT07861074Updated Nov 16, 2026

A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)

A Phase 2 interventional study of Tulisokibart and Placebo in Noninfectious Intermediate, Posterior, or Panuveitis, sponsored by Merck Sharp & Dohme LLC. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Now RecruitingFirst sites in United States and Canada+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Panuveitis with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Panuveitis · United States.

Planned enrollment
9th of 26
87 · median 34
Started
2026
the only one that year
Phase 2
7 of 28
1 open now
Registered
28th of 28
by date
Lead sponsor
1 of 28
Merck Sharp & Dohme LLC

Among the 28 studies in Panuveitis with a site in United States, this one is the 9th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2026, is one of 7 in phase 2, and was the 28th registered.

Panuveitis

39 studies on the registry are indexed under Panuveitis; 4 are open to participants now.

Browse Panuveitis studies →

Open to participants now

2 of the 28 studies in Panuveitis with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Panuveitis studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Panuveitis with a site in United States, or all of them as a file.
02

Study summary

This trial will help researchers learn if tulisokibart, the trial medicine, can treat non-infectious intermediate, posterior, or panuveitis (NIIPPU) so that steroids can be given for a shorter period of time. In this trial, researchers will look at different doses (amounts) of tulisokibart.

The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until NIIPPU gets worse. A placebo looks like the trial medicine but has no medicine in it. Using a placebo helps researchers better understand the effects of the trial medicine.

Read the detailed description

This study consists of a 50-week Double-blind Period and a 134-week Long-term Extension.

03

Conditions studied

  • Noninfectious Intermediate, Posterior, or Panuveitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has active noninfectious intermediate uveitis, posterior uveitis, or panuveitis (NIIPPU) at screening and baseline in at least one eye
  • Meets prior stable dose and duration requirements before baseline for permitted therapies and

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has isolated anterior uveitis
  • Has macular edema as the only sign of intermediate, posterior, or panuveitis
  • Has active ocular disease that may confound assessment or is not adequately controlled
  • Has significant ocular comorbidity that would interfere with visualization or study assessments
  • Has planned ocular surgery during the double-masked treatment period
  • Has had recent ocular surgery or ocular laser procedure that could affect study assessments
  • Has had major surgery within 3 months prior to Screening or has major surgery planned during the study
  • Has a to mydriatic eye drops or cannot be adequately dilated for fundus - visualization
  • Has any condition preventing evaluation of both eyes for eligibility or efficacy assessments
  • Has any other immune-mediated inflammatory condition that is not well controlled and may require prohibited therapy
  • Has a transplanted organ requiring continued systemic
  • Has active infection
  • Has a recent history of that is not considered adequately resolved
  • Has had a recent diagnostic evaluation for malignancy where malignancy cannot be reasonably excluded
  • Has demonstrated intolerance to or prior inadequate response to high-dose oral for the study indication
  • Has known allergies, , or intolerance to the study drug and other medications, dyes
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
87 participants (estimated)

Study arms

  • Experimental
    Tulisokibart Low Dose

    Participants receive background therapy of prednisone plus a high dose of tulisokibart.

    Drug: Tulisokibart · Drug: Background prednisone therapy

  • Experimental
    Tulisokibart High Dose

    Participants receive background therapy of prednisone plus a low dose of tulisokibart.

    Drug: Tulisokibart · Drug: Background prednisone therapy

  • Placebo comparator
    Placebo

    Participants receive background therapy of prednisone plus placebo to tulisokibart.

    Drug: Placebo · Drug: Background prednisone therapy

Interventions

  • Subcutaneous (SC) administration

    Also known as: MK-7240, PRA023

  • DrugPlacebo

    SC administration

  • DrugBackground prednisone therapy

    Oral administration

06

What researchers measure

Primary outcomes

  1. Time to Treatment Failure Occurring on or After Week 6 Through Week 50

    The time to treatment failure is the interval from the date of first study dose intervention to the earliest assessment date on which any protocol-specified treatment failure criterion is met. The time to treatment failure occurring on or after Week 6 through Week 50 will be reported.

    Time frame: up to 44 weeks

Secondary outcomes

  1. Percentage of Participants with Treatment Failure Occurring on or After Week 6 Through Week 26

    The time to treatment failure is the interval from the date of first study dose intervention to the earliest assessment date on which any protocol-specified treatment failure criterion is mat. The percentage of participants with treatment failure treatment failure occurring on or after Week 6 through Week 26 will be reported.

    Time frame: Up to 20 weeks

  2. Mean Change in Vitreous Haze (VH) Grade from Best State Achieved Prior to Week 6 up to Week 50

    VH Grade will be assessed by dilated indirect ophthalmoscopy in accordance with the National Eye Institute/ Standardization of Uveitis Nomenclature criteria with grades ranging from 0 (no evident vitreal haze) to 4+ (optic nerve head is obscured) with a higher grade indicating a greater amount of VH. The mean change in VH grade from best state achieved prior to Week 6 up to Week 50 will be reported.

    Time frame: Baseline and up to Week 50

  3. Mean Change in Logarithm of the Minimal Angle of Resolution Best Corrected Visual Acuity (BCVA) from Best State Achieved Prior to Week 6 up to Week 26

    Refraction will be performed in the participant's study eye, and using the appropriate corrective lenses, BRCA will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The BCVA scores will be converted to a log scale and reported as the logarithm of the minimal angle of resolution (logMAR) BCVA. The mean change from best state achieved prior to Week 6 up to Week 26 will be reported.

    Time frame: Baseline and up to Week 26

  4. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.

    Time frame: Up to 198 weeks

  5. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.

    Time frame: Up to 184 weeks

07

Study locations

2 of 2 sites recruiting
  • Texas Retina Associates ( Site 0006)
    Plano, Texas 75075, United States
    Recruiting
    • Study Coordinator · Contact214-706-0438
  • West Coast Retina Consultants - West Broadway ( Site 0505)
    Vancouver, British Columbia V5Z 1K1, Canada
    Recruiting
    • Study Coordinator · Contact6048751661
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Jun 2029, 31 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartActual
Nov 4, 2026was Oct 2026
Primary completionEst.
Jun 5, 2029
CompletionEst.
Apr 10, 2032
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
2 sites added — first sites in United States and Canada
Show 2 added (1 United States, 1 Canada)
  • Texas Retina Associates ( Site 0006) · Plano, United States
  • West Coast Retina Consultants - West Broadway ( Site 0505) · Vancouver, Canada
across 2 updates, Nov 9, 2026 – Nov 16, 2026
Start date
Oct 27, 2026→Nov 4, 2026 (actual)
Nov 9, 2026
Study completion
Apr 6, 2032→Apr 10, 2032
Nov 9, 2026
Contact
Study contact now listed: added T•••@msd.com · •••8839. See the current contact
Nov 9, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 3 updates
  1. Nov 16, 2026
    1 site added — first site in Canada
    Show site
    • West Coast Retina Consultants - West Broadway ( Site 0505) · Vancouver, Canada
    + 1 other change: references
  2. Nov 9, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Texas Retina Associates ( Site 0006) · Plano, United States
    Start date Oct 27, 2026→Nov 4, 2026 (now actual)
    Study completion Apr 6, 2032→Apr 10, 2032
    Contact Study contact now listed: added T•••@msd.com · •••8839. See the current contact
    + 1 other change: verification date
  3. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861074
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Nov 4, 2026
Primary completion
Jun 5, 2029 (estimated)
Completion
Apr 10, 2032 (estimated)
Last update
Nov 16, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tulisokibart

Start the discussion